fda bpc-157 warning letter 📢 News: Today, Dyne Therapeutics announced that the company has submitted a BLA to the for z-rostudirsen for individuals living with #Duchenne who are amenable to exon 51 skipping. The company FDA Panel Supports Lifting Restrictions

Common reasons Dose too low - may need to increase to therapeutic levels (2.4mg or higher) Not enough time - meaningful results typically take 8-12 weeks at adequate doses Calorie-dense liquid calories bypassing satiety signals - watch smoothies, alcohol, sugary drinks Eating through fullness signals - pay attention to your body's cues Inconsistent dosing schedule - must be same day each week for optimal levels Unrealistic expectations - 1-2 lbs per week is healthy, sustainable weight loss Key Research [1]"Once-weekly cagrilintide for weight management in people with overweight and obesity" Lau DCW et al., 2021 Finding: Phase 2 trial showed cagrilintide at 4.5mg achieved 10.8% weight loss versus 3% with placebo over 26 weeks in 706 participants

10.1371/journal.pone.0162590 41 LueticK.SucicM.VlainicJ.HalleZ

Furthermore, cerebral endothelial miR-144 downregulates claudin-5, Claudin-12, occludin, and ZO-1, ZO-2, and ZO-3 in a model of BBB permeability associated with a blood-tumor barrier (Cai et al., 2016)

Starting cagrilintide when already on retatrutide If you are already established on retatrutide at a stable dose (meaning you have been at your current retatrutide dose for at least four weeks without significant GI issues), you can introduce cagrilintide at its lowest starting dose of 0.25 mg weekly

What it feels like : Constant hunger, especially in the first 13 weeks Cravings for carbohydrates and salty foods Difficulty staying in a caloric deficit How to manage : Dose at night to sleep through the appetite surge Eat higher fiber and protein meals to blunt hunger Stay hydratedghrelin rises when dehydrated Use Greens + Reds for gut satisfaction and micronutrient density Ghrelin receptor activation by MK-677 leads to dose-dependent appetite stimulation, with the effect diminishing over time as tolerance builds. Smith et al., The Journal of Clinical Endocrinology & Metabolism 2

Key Features Research Use Only (RUO) compound 5 mg per bottle Spray format for convenient handling in laboratory settings Manufactured and packaged for research applications Product Specifications Compound Name: DSIP Form: Spray Total Quantity: 5 mg per bottle Grade: Research Use Only (RUO) Intended Use This product is intended solely for laboratory research and investigational purposes